Bayer Shareholders Keep the Squeeze on CEO Over Roundup Saga

As Bayer AG tries to draw a line under costly Roundup herbicide litigation in the US this year, shareholders made clear at its annual general meeting that the stakes are higher than ever — including for Chief Executive Officer Bill Anderson.

Anderson told investors Friday that the company has made “great progress” over the past two years, pointing to a stronger drug pipeline and advances in efforts to contain the legal fallout from its $63 billion Monsanto acquisition in 2018. But he also cautioned that “the work isn’t complete. Yet.”